| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8446919 | European Journal of Cancer | 2011 | 9 Pages |
Abstract
Linifanib demonstrated clinically meaningful activity in patients with advanced RCC after sunitinib failure. At 0.25Â mg/kg/day, significant dose modifications were required. An alternative, fixed-dosing strategy is being evaluated in other trials.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Nizar M. Tannir, Yu-Ning Wong, Christian K. Kollmannsberger, Marc S. Ernstoff, David J. Perry, Leonard J. Appleman, Edwin M. Posadas, Daniel Cho, Toni K. Choueiri, Andrew Coates, Neeraj Gupta, Rajendra Pradhan, Jiang Qian, Jihong Chen,